Fluicell AB (publ) (FLUI.ST)
SEK 0.04
(0.5%)
SEK 0.04
(0.5%)
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2023 | 3.15 Million SEK | 103.62% |
| 2022 | 1.54 Million SEK | -15.92% |
| 2021 | 1.84 Million SEK | -3.77% |
| 2020 | 1.91 Million SEK | 133.74% |
| 2019 | 818 Thousand SEK | -12.61% |
| 2018 | 936 Thousand SEK | 6.73% |
| 2017 | 877 Thousand SEK | 97.97% |
| 2016 | 443 Thousand SEK | 2.78% |
| 2015 | 431 Thousand SEK | 38.59% |
| 2014 | 311 Thousand SEK | 0.0% |
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2024 Q1 | 3.08 Million SEK | -2.03% |
| 2024 Q2 | 3.03 Million SEK | -1.72% |
| 2023 FY | 3.15 Million SEK | 103.62% |
| 2023 Q1 | 2.36 Million SEK | 52.94% |
| 2023 Q2 | 2.76 Million SEK | 16.82% |
| 2023 Q4 | 3.15 Million SEK | 2.97% |
| 2023 Q3 | 3.05 Million SEK | 10.67% |
| 2022 Q2 | 1.65 Million SEK | 7.41% |
| 2022 Q4 | 1.54 Million SEK | -5.09% |
| 2022 Q1 | 1.53 Million SEK | -16.36% |
| 2022 FY | 1.54 Million SEK | -15.92% |
| 2022 Q3 | 1.63 Million SEK | -1.39% |
| 2021 Q1 | 1.95 Million SEK | 2.41% |
| 2021 FY | 1.84 Million SEK | -3.77% |
| 2021 Q4 | 1.84 Million SEK | -20.24% |
| 2021 Q3 | 2.3 Million SEK | -12.75% |
| 2021 Q2 | 2.64 Million SEK | 35.04% |
| 2020 Q4 | 1.91 Million SEK | -0.78% |
| 2020 Q1 | 980 Thousand SEK | 19.8% |
| 2020 Q2 | 2.03 Million SEK | 107.76% |
| 2020 Q3 | 1.92 Million SEK | -5.35% |
| 2020 FY | 1.91 Million SEK | 133.74% |
| 2019 Q1 | 764 Thousand SEK | -18.38% |
| 2019 FY | 818 Thousand SEK | -12.61% |
| 2019 Q4 | 818 Thousand SEK | 0.49% |
| 2019 Q3 | 814 Thousand SEK | 8.53% |
| 2019 Q2 | 750 Thousand SEK | -1.83% |
| 2018 Q3 | 824 Thousand SEK | 4.83% |
| 2018 FY | 936 Thousand SEK | 6.73% |
| 2018 Q2 | 786 Thousand SEK | -9.03% |
| 2018 Q1 | 864 Thousand SEK | -1.48% |
| 2018 Q4 | 936 Thousand SEK | 13.59% |
| 2017 Q1 | - SEK | -100.0% |
| 2017 Q4 | 877 Thousand SEK | 0.0% |
| 2017 FY | 877 Thousand SEK | 97.97% |
| 2016 FY | 443 Thousand SEK | 2.78% |
| 2016 Q4 | 443.19 Thousand SEK | 0.0% |
| 2015 FY | 431 Thousand SEK | 38.59% |
| 2014 FY | 311 Thousand SEK | 0.0% |
| Name | Inventory | Inventory Difference |
|---|---|---|
| Alligator Bioscience AB (publ) | 2.00 SEK | -157499900.0% |
| Ziccum AB (publ) | -4.18 Million SEK | 175.197% |
| Modus Therapeutics Holding AB (publ) | - SEK | -Infinity% |
| BioArctic AB (publ) | - SEK | -Infinity% |
| Sprint Bioscience AB (publ) | -7.13 Million SEK | 144.142% |
| Mendus AB (publ) | - SEK | -Infinity% |
| Genovis AB (publ.) | 14.9 Million SEK | 78.866% |
| Intervacc AB (publ) | 10.48 Million SEK | 69.951% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | - SEK | -Infinity% |
| Active Biotech AB (publ) | -2500.00 SEK | 126100.0% |
| Magle Chemoswed Holding AB (publ) | 35.22 Million SEK | 91.059% |
| Bio-Works Technologies AB (publ) | 9.06 Million SEK | 65.262% |
| Aptahem AB (publ) | - SEK | -Infinity% |
| Vicore Pharma Holding AB (publ) | - SEK | -Infinity% |
| Kancera AB (publ) | -1950.00 SEK | 161638.462% |
| Infant Bacterial Therapeutics AB (publ) | - SEK | -Infinity% |
| Saniona AB (publ) | 1.00 SEK | -314999900.0% |
| Lipigon Pharmaceuticals AB (publ) | -1.62 Million SEK | 293.727% |
| Biovica International AB (publ) | 2.19 Million SEK | -43.247% |
| Spago Nanomedical AB (publ) | 1.00 SEK | -314999900.0% |
| AcouSort AB (publ) | 2.08 Million SEK | -51.442% |
| Xintela AB (publ) | 398 Thousand SEK | -691.457% |
| Abliva AB (publ) | - SEK | -Infinity% |
| Egetis Therapeutics AB (publ) | 700 Thousand SEK | -350.0% |
| Karolinska Development AB (publ) | - SEK | -Infinity% |
| OncoZenge AB (publ) | -862.99 Thousand SEK | 465.006% |
| Amniotics AB (publ) | 534 Thousand SEK | -489.888% |
| 2cureX AB (publ) | -1000.00 SEK | 315100.0% |
| CombiGene AB (publ) | -1.79 Million SEK | 275.097% |
| Asarina Pharma AB (publ) | - SEK | -Infinity% |
| Calliditas Therapeutics AB (publ) | 20.42 Million SEK | 84.58% |
| Camurus AB (publ) | 100.95 Million SEK | 96.88% |
| Corline Biomedical AB | -3.85 Million SEK | 181.67% |
| IRLAB Therapeutics AB (publ) | 1000.00 SEK | -314900.0% |
| Isofol Medical AB (publ) | - SEK | -Infinity% |
| I-Tech AB | 4.28 Million SEK | 26.402% |
| Hansa Biopharma AB (publ) | 9.79 Million SEK | 67.831% |
| Cyxone AB (publ) | - SEK | -Infinity% |
| ExpreS2ion Biotech Holding AB (publ) | - SEK | -Infinity% |
| Biosergen AB | -4.92 Million SEK | 163.907% |
| Cantargia AB (publ) | - SEK | -Infinity% |
| NextCell Pharma AB | 545.23 Thousand SEK | -477.73% |
| Xspray Pharma AB (publ) | 43.78 Million SEK | 92.805% |
| Elicera Therapeutics AB (publ) | -446.98 Thousand SEK | 804.72% |
| Nanologica AB (publ) | 2.97 Million SEK | -5.954% |
| SynAct Pharma AB | - SEK | -Infinity% |
| Annexin Pharmaceuticals AB (publ) | - SEK | -Infinity% |
| Stayble Therapeutics AB (publ) | -321.14 Thousand SEK | 1080.865% |
| LIDDS AB (publ) | - SEK | -Infinity% |
| Lipum AB (publ) | - SEK | -Infinity% |
| BioInvent International AB (publ) | 11.84 Million SEK | 73.404% |
| Alzinova AB (publ) | -3.27 Million SEK | 196.095% |
| Oncopeptides AB (publ) | 2.42 Million SEK | -29.897% |
| Pila Pharma AB (publ) | 1.00 SEK | -314999900.0% |
| Guard Therapeutics International AB (publ) | -1486.00 SEK | 212078.466% |
| Scandinavian ChemoTech AB (publ) | 4.03 Million SEK | 21.914% |
| Simris Alg AB (publ) | 1.09 Million SEK | -188.726% |
| Diamyd Medical AB (publ) | 24.05 Million SEK | 86.902% |
| Xbrane Biopharma AB (publ) | 106.85 Million SEK | 97.052% |
| Ascelia Pharma AB (publ) | - SEK | -Infinity% |
| Diagonal Bio AB (publ) | 1.02 Million SEK | -206.42% |